Resumen
La tuberculosis se ha incrementado en todo el mundo. Comunicamos el caso de un paciente con meningoencefalitis tuberculosa y tuberculosis de hueso (mal de Pott), que sufrió una reacción adversa grave a los fármacos antituberculosos. Inició con farmacodermia, hepatitis, leucocitosis, eosinofilia y fiebre, que constituyen el síndrome DRESS. Este síndrome es una reacción grave de hipersensibilidad a diferentes fármacos. Suele ser producido por anticonvulsivos, sulfonamidas y algunos fármacos antivirales, entre otros. Los fármacos antituberculosos también pueden producir este síndrome potencialmente fatal. Se destaca la importancia de la farmacovigilancia para su detección y tratamiento tempranos.
Referencias
Bocquet H, Boagot M, Roujeau JC. Drug-induced pseudolymphoma and drug hypersensitivity (drug rash with eosinophilia and systemic symptoms: DRESS). Semin Cutan Med Surg 1996;15:250-257.
Walsh SA, Creamer D. Drug reaction with eosinophilia and systemic symptoms (DRESS): a clinical update and review of current thinking. Clinical and Experimental Dermatology 2011;36:6-11.
Bopaka RG, El Khattabi W, Afif H, Aichane A, Bouayad Z. The “DRESS” syndrome in antituberculosis drugs. Rev Pneumol Clin 2014;70:185.
Eshki M, Allanore L, Musette P, et al. Twelve-year analysis of severe cases of drug reaction with eosinophilia and systemic symptoms: a cause of unpredictable multiorgan failure. Arch Dermatol 2009;145:67-72.
Shebe K, Ngwanya MR, Gantsho N, Lehloenya RJ. Severe recurrence of drug rash with eosinophilia and systemic symptoms syndrome secondary to rifampicin patch testing in a human immunodeficiency virus-infected man. Contact Dermatitis 2014;70:125-127.
World Health Organization. Guidelines for the programmatic management of drug resistant tuberculosis, 2011 update. Geneva: WHO 2011, WHO/HTM/TB/2011.6.
Programa de control de la tuberculosis. Ministerio de Salud Pública del Ecuador. Manual de normas y procedimientos para el control de la tuberculosis en Ecuador. 2ª ed. 2010.
Katsube O, Anzai M, Nomura Y, Ikeda N, et al. A case of drug-induced hypersensitivity syndrome caused by levofloxacin used for treating pulmonary tuberculosis. Kekkaku 2014;89:51-56.
Husain Z, Reddy BY, Schwartz RA. DRESS syndrome: part II. Management and therapeutics. J Am Acad Dermatol 2013;68:709,718-720.
Shiohara T, Kano Y, Takahashi R. Current concepts on the diagnosis and pathogenesis of drug-induced hypersensitivity syndrome. JMAJ 2009;52:347-352.
Criado PR, Criado RFJ, Avancini J, et al. Drug reaction with eosinophilia and systemic symptoms (DRESS)/drug-induced hypersensitivity syndrome (DIHS): a review of current concepts. An Bras Dermatol 2012;87:435-449.
Cacoub P, Musette P, Descamps V, et al. The DRESS syndrome: A literature review. Am J Med 2011;124:588-597.
Bauer KA, Brimhall AK, Chang TT: Drug reaction with eosinophilia and systemic symptoms (DRESS) associated with azithromycin in acute Epstein-Barr virus infection. Pediatr Dermatol 2011;28:741-743.
Wang XQ, Lang SY, Shi XB, et al. Cross-reactivity of skin rashes with current antiepileptic drugs in Chinese population. Seizure 2012;19:562.
Kish DD, Volokh N, Baldwin WM III, Fairchild RL. Hapten application to the skin induces an inflammatory program directing hapten-primed effector CD8 T cell interaction with hapten-presenting endothelial cells. J Immunol 2011;186:2117-2126.
Ahmed R, Cooper R, Foisy M, Der E, Kunimoto D. Factors associated with reduced antituberculous serum drug concentration in patients with HIV-TB coinfection. J Int Assoc Physicians AIDS Care 2012;11:273-276.
Wang F, Li Y, Mo Y, Shen C, et al. Cutaneous adverse drug reactions: an 8-year retrospective study on hospitalized patients in Southern China. Indian J Dermatol Venereol Leprol 2012;78:488-490.
Kaswala DH. Drug rash with eosinophilia and systemic symptoms syndrome due to anti-TB medication. J Family Med Prim Care 2013;2:83-85.
Bloss E, Chan PC, Cheng NW, et al. Increasing directly observed therapy related to improved tuberculosis treatment outcomes in Taiwan. Int J Tuberc Lung Dis 2012;16:462-467.
Moonan PK, Quitugua TN, Pogoda JM, et al. Does directly observed therapy (DOT) reduce drug resistant tuberculosis? BMC Public Health 2011;11:19.
Prasad K, Singh MB. Corticosteroids for managing tuberculosis meningitis. Cochrane Database Syst Rev 2013;23:CDC002244.
Pan-Canadian Public Health Network. Guidance for tuberculosis prevention and control programs in Canada: Ottawa: Government of Canada 2013. Disponible en: http://www.phn-rsp.ca/pubs/index-eng.php
Cacoub P, Musette P, Descamps V, Meyer O, et al. The DRESS syndrome: a literature review. Am J Med 2011;124:588.
Esta obra está bajo una licencia internacional Creative Commons Atribución-NoComercial 4.0.
Derechos de autor 2015 Revista Alergia México